{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T21:46:10Z","timestamp":1782510370178,"version":"3.54.5"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ucl.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T21:52:13Z","timestamp":1777499533000},"page":"343-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epidemiology and Risk Factors for Non\u2013Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Olutiwa","family":"Akinsola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maheetha","family":"Bharadwaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah P.","family":"Psutka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ucl.2026.03.001_bib1","series-title":"Cancer of the urinary bladder \u2013Cancer stat facts","year":"2025"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.001_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eururo.2011.03.047","article-title":"Trends in mortality from urologic cancers in Europe, 1970-2008","volume":"60","author":"Bosetti","year":"2011","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.001_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.001_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.eururo.2015.06.042","article-title":"The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks","volume":"70","author":"Cumberbatch","year":"2016","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.001_bib5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"218","key":"10.1016\/j.ucl.2026.03.001_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/03008880802325192","article-title":"A meta-analysis on the association between bladder cancer and occupation","author":"Reulen","year":"2008","journal-title":"Scand J Urol Nephrol Suppl"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.001_bib7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1097\/JOM.0000000000002919","article-title":"Gross hematuria and lower urinary tract symptoms associated with military burn pits exposures in US veterans deployed to Iraq and Afghanistan","volume":"65","author":"Perveen","year":"2023","journal-title":"J Occup Environ Med"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/oemed-2013-101662","article-title":"Mortality and cancer incidence in a pooled cohort of US firefighters from San Francisco, Chicago and Philadelphia (1950-2009)","volume":"71","author":"Daniels","year":"2014","journal-title":"Occup Environ Med"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.20593","article-title":"Exposure to agent Orange and risk of bladder cancer among US veterans","volume":"6","author":"Williams","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.ucl.2026.03.001_bib10","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.urolonc.2012.04.006","article-title":"The characteristics of bladder cancer after radiotherapy for prostate cancer","volume":"31","author":"Abern","year":"2013","journal-title":"Urol Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.001_bib11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1093\/jnci\/87.7.524","article-title":"Bladder and kidney cancer following cyclophosphamide therapy for non-hodgkin\u2019s lymphoma","volume":"87","author":"Travis","year":"1995","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.001_bib12","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2026.03.001_bib13","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1002\/ijc.33486","article-title":"Bladder cancer risk associated with family history of cancer","volume":"148","author":"Koutros","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ucl.2026.03.001_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2024.08.011","article-title":"Hereditary and familial traits in urological cancers and their underlying genes","volume":"69","author":"Hemminki","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.001_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.urolonc.2008.02.016","article-title":"Familial and genetic risk of transitional cell carcinoma of the urinary tract","volume":"26","author":"Mueller","year":"2008","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/ejhg.2013.251","article-title":"HRAS mutations in bladder cancer at an early age and the possible association with the Costello syndrome","volume":"22","author":"Beukers","year":"2014","journal-title":"Eur J Hum Genet : EJHG (Eur J Hum Genet)"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.001_bib17","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1634\/theoncologist.2019-0846","article-title":"Emerging therapeutic implications of STK11 mutation: case series","volume":"25","author":"Laderian","year":"2020","journal-title":"Oncologist"},{"issue":"23","key":"10.1016\/j.ucl.2026.03.001_bib18","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1002\/cncr.30248","article-title":"Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort","volume":"122","author":"Mai","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.001_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1897-4287-7-4","article-title":"The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype","volume":"7","author":"Ruijs","year":"2009","journal-title":"Hered Cancer Clin Pract"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.001_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jpurol.2020.04.021","article-title":"The association of neurofibromatosis type 1 and lower urinary tract dysfunction in the paediatric population - a critical review of literature","volume":"16","author":"Gao","year":"2020","journal-title":"J Pediatr Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.001_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in Situ)-A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2026.03.001_bib23","doi-asserted-by":"crossref","first-page":"106.e1","DOI":"10.1016\/j.urolonc.2021.10.008","article-title":"Bladder cancer (NMIBC) in a population-based cohort from Stockholm county with long-term follow-up; A comparative analysis of prediction models for recurrence and progression, including external validation of the updated 2021 E.A.U. model","volume":"40","author":"Dovey","year":"2022","journal-title":"Urol Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.001_bib24","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.001_bib25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","article-title":"NCCN guidelines\u00ae insights: bladder cancer, version 3.2024","volume":"22","author":"Flaig","year":"2024","journal-title":"J Natl Compr Cancer Netw : J Natl Compr Cancer Netw"},{"key":"10.1016\/j.ucl.2026.03.001_bib26","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, screening, and prevention of bladder cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"6 Suppl 4","key":"10.1016\/j.ucl.2026.03.001_bib28","article-title":"Screening for bladder cancer: the best opportunity to reduce mortality","volume":"3","author":"Fradet","year":"2009","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.001_bib29","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/JU.0000000000003981","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/SUO guideline (2017; amended 2020, 2024)","volume":"212","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.ucl.2026.03.001_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2022.02.011","article-title":"Comparative outcomes of primary versus recurrent high-risk non-muscle-invasive and primary versus secondary muscle-invasive bladder cancer after radical cystectomy: results from a retrospective multicenter study","volume":"39","author":"Grossmann","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib31","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s41669-024-00512-8","article-title":"Economic impact of bladder cancer in the USA","volume":"8","author":"Clark","year":"2024","journal-title":"PharmacoEconomics-Open"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.001_bib32","doi-asserted-by":"crossref","DOI":"10.1097\/JU.0000000000004567","article-title":"Updates to microhematuria: AUA\/SUFU guideline (2025)","volume":"214","author":"Barocas","year":"2025","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.001_bib33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2018.03.008","article-title":"Who should be investigated for haematuria? Results of a contemporary prospective observational study of 3556 patients","volume":"74","author":"Tan","year":"2018","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.001_bib34","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/cncr.22224","article-title":"Long-term outcome of hematuria home screening for bladder cancer in men","volume":"107","author":"Messing","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2026.03.001_bib35","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2340\/sju.v58.11142","article-title":"Abandoning testing for asymptomatic microscopic haematuria in Sweden-a long-term follow-up","volume":"58","author":"Malmstr\u00f6m","year":"2023","journal-title":"Scand J Urol"},{"issue":"7393","key":"10.1016\/j.ucl.2026.03.001_bib36","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.326.7393.813","article-title":"Time to abandon testing for microscopic haematuria in adults?","volume":"326","author":"Malmstr\u00f6m","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ucl.2026.03.001_bib37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2340\/sju.v58.11142","article-title":"Abandoning testing for asymptomatic microscopic haematuria in Sweden - a long-term follow-up","volume":"58","author":"Malmstr\u00f6m","year":"2023","journal-title":"Scand J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.03.001_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.56434\/j.arch.esp.urol.20237602.12","article-title":"Impact of a one-stop hematuria clinic on overall survival and bladder tumor recurrence","volume":"76","author":"Rodr\u00edguez","year":"2023","journal-title":"Arch Esp Urol"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.001_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-076612","article-title":"Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk","volume":"13","author":"Catto","year":"2023","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.001_bib40","first-page":"412","article-title":"Urine cytology and adjunct markers for detection and surveillance of bladder cancer","volume":"2","author":"Sullivan","year":"2010","journal-title":"Am J Transl Res"},{"issue":"9","key":"10.1016\/j.ucl.2026.03.001_bib41","first-page":"882","article-title":"Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement","volume":"5","author":"Reid","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.001_bib42","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1001\/jama.293.7.810","article-title":"Detection of bladder cancer using a point-of-care proteomic assay","volume":"293","author":"Grossman","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ucl.2026.03.001_bib43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-230096","article-title":"Noninvasive tests for bladder cancer detection and surveillance: a systematic review of commercially available assays","volume":"10","author":"Heard","year":"2024","journal-title":"Bladder Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.001_bib44","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/S0022-5347(05)67104-2","article-title":"A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma","volume":"164","author":"Halling","year":"2000","journal-title":"J Urol"},{"issue":"18","key":"10.1016\/j.ucl.2026.03.001_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241814374","article-title":"Molecular markers for bladder cancer screening: an insight into bladder cancer and FDA-approved biomarkers","volume":"24","author":"Flores Monar","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib46","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1245\/s10434-016-5763-5","article-title":"Anticipatory positive urine tests for bladder cancer","volume":"24","author":"Gopalakrishna","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"10.1016\/j.ucl.2026.03.001_bib47","article-title":"Adenomatous polyposis coli (APC) promoter gene methylation in urine-derived DNA: a non-invasive biomarker for early bladder cancer detection and tumor aggressiveness","volume":"16","author":"Aqerrout","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.ucl.2026.03.001_bib48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ucl.2026.03.001_bib49","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/j.1464-410X.2008.07473.x","article-title":"Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection","volume":"101","author":"Lotan","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2026.03.001_bib50","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/S0022-5347(05)64270-X","article-title":"Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer","volume":"168","author":"Sarosdy","year":"2002","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.001_bib51","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40273-024-01463-y","article-title":"Home urine dipstick screening for bladder and kidney cancer in high-risk populations in England: a microsimulation study of long-term impact and cost-effectiveness","volume":"43","author":"Mandrik","year":"2025","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.ucl.2026.03.001_bib52","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41416-023-02357-0","article-title":"Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers","volume":"129","author":"Shala","year":"2023","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib53","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/jnci\/93.6.427","article-title":"Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine","volume":"93","author":"Hemstreet","year":"2001","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/ajim.20160","article-title":"Mortality in Florida professional firefighters, 1972 to 1999","volume":"47","author":"Ma","year":"2005","journal-title":"Am J Ind Med"},{"key":"10.1016\/j.ucl.2026.03.001_bib55","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0022-5347(08)60945-3","article-title":"Results from the San Fransisco firefighters bladder cancer screening study","volume":"179","author":"Greene","year":"2008","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2026.03.001_bib56","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ajur.2022.05.009","article-title":"Genitourinary manifestations of Lynch syndrome in the urological practice","volume":"9","author":"Lonati","year":"2022","journal-title":"Asian J Urol"},{"key":"10.1016\/j.ucl.2026.03.001_bib57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10689-008-9193-9","article-title":"Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer","volume":"7","author":"Myrh\u00f8j","year":"2008","journal-title":"Fam Cancer"},{"key":"10.1016\/j.ucl.2026.03.001_bib58","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1464-410X.2010.09443.x","article-title":"Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma","volume":"106","author":"Acher","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2026.03.001_bib59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1470-2045(09)70041-5","article-title":"Management of extracolonic tumours in patients with Lynch syndrome","volume":"10","author":"Koornstra","year":"2009","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ucl.2026.03.001_bib60","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1097\/JU.0000000000003480","article-title":"Diagnosis and management of non-metastatic upper tract urothelial carcinoma: AUA\/SUO guideline","volume":"209","author":"Coleman","year":"2023","journal-title":"J Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:56:07Z","timestamp":1782507367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0094014326000273"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.001","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and Risk Factors for Non\u2013Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}